As of June 30, 2025, the Company had cash and cash equivalents of $7.6 million and believes that the cash on hand is sufficient to fund planned operations into the fourth quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Promising Developments in Annamycin Drive Buy Rating for Moleculin Biotech
- Moleculin Biotech (MBRX) Q2 Earnings Cheat Sheet
- Moleculin Biotech Reveals Promising Preclinical Data for Annamycin
- Moleculin Biotech announces preclinical data of annamycin in liver cancer
- Moleculin Biotech Releases Corporate Presentation Update